Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201700412> ?p ?o ?g. }
- W3201700412 endingPage "121162" @default.
- W3201700412 startingPage "121162" @default.
- W3201700412 abstract "Antibodies targeting the CD40-CD40L pathway have great potential for treating autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus (SLE), lupus nephritis (LN), and inflammatory bowel diseases (IBD). However, in addition to the known difficulty in generating a purely antagonistic CD40 antibody, the presence of CD40 and CD40L on platelets creates additional unique challenges for the safety, target coverage, and clearance of antibodies targeting this pathway. Previously described therapeutic antibodies targeting this pathway have various shortcomings, and the full therapeutic potential of this axis has yet to be realized. Herein, we describe the generation and characterization of BI 655064, a novel, purely antagonistic anti-CD40 antibody that potently neutralizes CD40-CD40L-dependent B-cell stimulation without evidence of impacting platelet functions. This uniquely optimized antibody targeting a highly challenging pathway was obtained by applying stringent functional and biophysical criteria during the lead selection process. BI 655064 has favorable target-mediated drug disposition (TMDD)-saturation pharmacokinetics, consistent with that of a high-quality therapeutic monoclonal antibody." @default.
- W3201700412 created "2021-10-11" @default.
- W3201700412 creator A5001242096 @default.
- W3201700412 creator A5005559132 @default.
- W3201700412 creator A5007007815 @default.
- W3201700412 creator A5013235355 @default.
- W3201700412 creator A5022552125 @default.
- W3201700412 creator A5026911712 @default.
- W3201700412 creator A5029852970 @default.
- W3201700412 creator A5047645413 @default.
- W3201700412 creator A5049985904 @default.
- W3201700412 creator A5050986216 @default.
- W3201700412 creator A5055329330 @default.
- W3201700412 creator A5058023044 @default.
- W3201700412 creator A5059164159 @default.
- W3201700412 creator A5062665642 @default.
- W3201700412 creator A5069083837 @default.
- W3201700412 creator A5079605350 @default.
- W3201700412 creator A5082529729 @default.
- W3201700412 creator A5087616644 @default.
- W3201700412 date "2021-11-01" @default.
- W3201700412 modified "2023-10-07" @default.
- W3201700412 title "An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases" @default.
- W3201700412 cites W1495428962 @default.
- W3201700412 cites W1514782836 @default.
- W3201700412 cites W1549160607 @default.
- W3201700412 cites W1581554632 @default.
- W3201700412 cites W1623137528 @default.
- W3201700412 cites W1670243206 @default.
- W3201700412 cites W1846632336 @default.
- W3201700412 cites W1964181260 @default.
- W3201700412 cites W1983918344 @default.
- W3201700412 cites W1990611578 @default.
- W3201700412 cites W1995926508 @default.
- W3201700412 cites W2000000588 @default.
- W3201700412 cites W2008367578 @default.
- W3201700412 cites W2015697331 @default.
- W3201700412 cites W2017390384 @default.
- W3201700412 cites W2019577361 @default.
- W3201700412 cites W2029957805 @default.
- W3201700412 cites W2030029123 @default.
- W3201700412 cites W2035070408 @default.
- W3201700412 cites W2057648030 @default.
- W3201700412 cites W2060004314 @default.
- W3201700412 cites W2060382742 @default.
- W3201700412 cites W2072930832 @default.
- W3201700412 cites W2083764534 @default.
- W3201700412 cites W2086267154 @default.
- W3201700412 cites W2087105697 @default.
- W3201700412 cites W2090877886 @default.
- W3201700412 cites W2100618302 @default.
- W3201700412 cites W2101492664 @default.
- W3201700412 cites W2102096193 @default.
- W3201700412 cites W2102583592 @default.
- W3201700412 cites W2118061894 @default.
- W3201700412 cites W2131555525 @default.
- W3201700412 cites W2133174218 @default.
- W3201700412 cites W2138384967 @default.
- W3201700412 cites W2151365509 @default.
- W3201700412 cites W2153908836 @default.
- W3201700412 cites W2161870927 @default.
- W3201700412 cites W2171594570 @default.
- W3201700412 cites W23912248 @default.
- W3201700412 cites W2470598491 @default.
- W3201700412 cites W2556710874 @default.
- W3201700412 cites W2767735239 @default.
- W3201700412 cites W2967833499 @default.
- W3201700412 cites W2967969561 @default.
- W3201700412 cites W3036398841 @default.
- W3201700412 cites W3102944374 @default.
- W3201700412 cites W3127542615 @default.
- W3201700412 cites W95996026 @default.
- W3201700412 doi "https://doi.org/10.1016/j.ijpharm.2021.121162" @default.
- W3201700412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34624444" @default.
- W3201700412 hasPublicationYear "2021" @default.
- W3201700412 type Work @default.
- W3201700412 sameAs 3201700412 @default.
- W3201700412 citedByCount "5" @default.
- W3201700412 countsByYear W32017004122022 @default.
- W3201700412 countsByYear W32017004122023 @default.
- W3201700412 crossrefType "journal-article" @default.
- W3201700412 hasAuthorship W3201700412A5001242096 @default.
- W3201700412 hasAuthorship W3201700412A5005559132 @default.
- W3201700412 hasAuthorship W3201700412A5007007815 @default.
- W3201700412 hasAuthorship W3201700412A5013235355 @default.
- W3201700412 hasAuthorship W3201700412A5022552125 @default.
- W3201700412 hasAuthorship W3201700412A5026911712 @default.
- W3201700412 hasAuthorship W3201700412A5029852970 @default.
- W3201700412 hasAuthorship W3201700412A5047645413 @default.
- W3201700412 hasAuthorship W3201700412A5049985904 @default.
- W3201700412 hasAuthorship W3201700412A5050986216 @default.
- W3201700412 hasAuthorship W3201700412A5055329330 @default.
- W3201700412 hasAuthorship W3201700412A5058023044 @default.
- W3201700412 hasAuthorship W3201700412A5059164159 @default.
- W3201700412 hasAuthorship W3201700412A5062665642 @default.
- W3201700412 hasAuthorship W3201700412A5069083837 @default.
- W3201700412 hasAuthorship W3201700412A5079605350 @default.
- W3201700412 hasAuthorship W3201700412A5082529729 @default.